Compare PRVA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | LIVN |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2021 | 2015 |
| Metric | PRVA | LIVN |
|---|---|---|
| Price | $23.71 | $80.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $31.17 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 1.1M | 513.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | 0.02 | ★ 0.40 |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $18.19 | $9.79 |
| Revenue Next Year | $10.72 | $6.63 |
| P/E Ratio | $1,197.00 | ★ $202.66 |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $18.92 | $41.13 |
| 52 Week High | $28.82 | $85.27 |
| Indicator | PRVA | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 50.87 |
| Support Level | $22.78 | $61.63 |
| Resistance Level | $24.65 | $80.96 |
| Average True Range (ATR) | 0.94 | 2.39 |
| MACD | -0.48 | -0.18 |
| Stochastic Oscillator | 4.62 | 60.77 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.